The company covers an area of 146 mu, with a total construction area of nearly 30,000 square meters. Construction in strict accordance with GMP standards, fixed assets investment1.200 million yuan. The first phase of the project started construction in February 2002, mainly including water injection workshop and office building, animal laboratory, product analysis center and water, electricity and steam supply projects. In April 2003, the first phase of the project successfully passed the national GMP certification and was officially put into production. The second phase of the project started in 1 month of 2004. At the same time, the GMP transformation of tablets, capsules, oral liquids and mixtures was carried out, and the small water injection workshop was expanded and the synthesis workshop was built. At the beginning of September, 2004, the workshops of tablets, capsules, oral liquids and mixtures successfully passed GMP certification. In 2005, it will pass the certification of Xiaoshui Town No.2 Workshop and Synthesis Workshop (API production workshop). At present, relevant certification materials have been reported to Henan Drug Administration.
Zhengzhou Ling Rui Pharmaceutical Co., Ltd. relies on the research and development advantages of Beijing Gaobo Pharmaceutical and Chemical Technology Center and Beijing Honghui Pharmaceutical Biotechnology Research Institute, and is committed to building the company into a leading technology enterprise in China. At present, the company has more than 0/00 batches of drugs, and Runtan injection, a new cerebrovascular drug, is an exclusive variety in China. The common injection products that occupy a large market share in China are dexamethasone sodium phosphate, glucose, ribavirin, antongding and houttuynia cordata injection.
After the completion of the company, the annual output of injections is more than 65.438+0.5 billion, capsules and tablets are 65.438+0.2 billion, and chemical raw materials (pharmaceutical intermediates) are 8 tons. The annual sales income is more than 600 million yuan, the profits and taxes are 65.438+0.2 billion yuan, and more than 654.38+0.000 employees are recruited. By then, the company will become the main manufacturer of small-volume injections and chemical raw materials in China and the most technologically advanced injection manufacturer in Henan Province.